Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
Year: 2023
Type: article
Study design: Clinical Trial
Source: Journal of Neuro-Oncology
Institutions: Wake Forest University Health Sciences, Wake Forest University, University of California, Los Angeles, Dana-Farber Cancer Institute, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, University of California, San Francisco, University of Pittsburgh, Johns Hopkins Hospital, University of Alabama at Birmingham, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4387845005
